Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Progestogen with antiandrogenic properties that is used for the treatment of conditions with hypersexuality, prostate carcinoma, transsexualism and, together with ethinyl estradiol, for hirsutism, acne and alopecia and hyperandrogenism in women.
It is excreted into breast milk in small quantities (Stoppelli 1980), but their anti-androgenic effects could be clinically significant for the infant when doses of 50 milligrams per day or higher are used.
The small amount (2 mg) contained in contraceptive tablets in which it is combined with ethinyl estradiol would represent a very low risk and would be compatible with breastfeeding.